Authors

Chris F. Taylor, European Bioinformatics Institute
Dawn Field, Natural Environment Research Council Environmental Bioinformatics Centre
Susanna-Assunta Sansone, European Bioinformatics Institute
Jan Aerts, Wellcome Trust Sanger Institute
Rolf Apweiler, European Bioinformatics Institute
Michael Ashburner, University of Cambridge
Catherine A. Ball, Stanford University School of Medicine
Pierre-Alain Binz, Swiss Institute of Bioinformatics
Molly Bogue, The Jackson Laboratory
Tim Booth, Natural Environment Research Council Environmental Bioinformatics Centre
Alvis Brazma, European Bioinformatics Institute
Ryan R. Brinkman, British Columbia Cancer Agency
Adam Michael Clark, The Lance Armstrong Foundation
Eric W. Deutsch, Institute for Systems Biology
Oliver Fiehn, University of California - Davis
Jennifer Fostel, National Institute of Environmental Health Sciences and Lockheed Martin Information Technology
Peter Chazal, University of Edinburgh Medical School
Frank Gibson, Newcastle University
Tanya Gray, Natural Environment Research Council Environmental Bioinformatics Centre
Graeme Grimes, University of Edinburgh Medical School
John M. Hancock, Bioinformatics Group
Nigel W. Hardy, Aberystwyth University
Henning Hermjakob, European Bioinformatics Institute
Randall K. Julian Jr., Indigo BioSystems, Inc.
Matthew Kane, National Science Foundation
Carsten Kettner, Beilstein-Institut zur Förderung der Chemischen Wissenschaften
Christopher Kinsinger, National Cancer Institute
Eugene Kolker, Seattle Children's Hospital Research Institute
Martin Kuiper, Vlaams Instituut voor Biotechnologie
Nicolas Le Novere, European Bioinformatics Institute
Jim Leebens-Mack, University of Georgia
Suzanna E. Lewis, University of California - Berkeley
Phillip Lord, Newcastle University
Ann-Marie Mallon, Bioinformatics Group
Nishanth Marthansan, University of Texas Southwestern Medical Center
Hiroshi Masuya, RIKEN Genomic Sciences Center
Ruth McNally, Lancaster University
Alexander Mehrle, German Cancer Research Center
Norman Morrison, Natural Environment Research Council Environmental Bioinformatics Centre
Sandra Orchard, European Bioinformatics Institute
John Quackbush, Harvard School of Public Health
James M. Reecy, Iowa State UniversityFollow
Donald G. Robertson, Bristol-Myers Squibb
Philippe Rocca-Serra, European Bioinformatics Institute
Henry Rodriguez, National Cancer Institute
Heiko Rosenfelder, German Cancer Research Center
Javier Santoyo-Lopez, University of Edinburgh Medical School
Richard H. Scheuermann, University of Texas Southwestern Medical Center
Daniel Schober, European Bioinformatics Institute
Barry Smith, University at Buffalo
Jason Snape, AstraZeneca UK Ltd.
Christian J. Stoeckert Jr., Center for Bioinformatics
Keith Tipton, Trinity College Dublin
Peter Sterk, European Bioinformatics Institute
Andreas Untergasser, Wageningen University
Jo Vandesompele, Ghent University Hospital
Stefan Wiemann, German Cancer Research Center

Document Type

Article

Publication Version

Published Version

Publication Date

2008

Journal or Book Title

Nature Biotechnology

Volume

26

First Page

889

Last Page

896

DOI

10.1038/nbt.1411

Abstract

To fully understand the context, methods, data and conclusions that pertain to an experiment, one must have access to a range of background information. However, the current diversity of experimental designs and analytical techniques complicates the discovery and evaluation of experimental data; furthermore, the increasing rate of production of those data compounds the problem. Community opinion increasingly favors that a regularized set of the available metadata ('data about the data') pertaining to an experiment1, 2 be associated with the results, making explicit both the biological and methodological contexts. Many journals and funding agencies now require that authors reporting microarray-based transcriptomics experiments comply with the Minimum Information about a Microarray Experiment (MIAME) checklist3 as a prerequisite for publication4, 5, 6, 7. Similarly, minimum information guidelines for reporting proteomics experiments and describing systems biology models are gaining broader support in their respective database communities8, 9; and progress is being made toward the standardization of the reporting of clinical trials in the medical literature10. Such minimum information checklists promote transparency in experimental reporting, enhance accessibility to data and support effective quality assessment, increasing the general value of a body of work (and the competitiveness of the originators).

Comments

This article is from Nature Biotechnology 26 (2008): 889, doi:10.1038/nbt.1411.

Rights

Works produced by employees of the U.S. Government as part of their official duties are not copyrighted within the U.S. The content of this document is not copyrighted.

Language

en

File Format

application/pdf

Share

COinS